DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xp9wx4/pharmacogenetics_a) has announced the addition of John Wiley and Sons Ltd's new book "Pharmacogenetics and Individualized Therapy" to their offering.

The One-Stop Reference To Pharmacogenetics And Its Impact On Pharmaceuticals, Therapeutics, And Clinical Practices

Pharmacogenetics and Individualized Therapy offers thorough coverage of the study of the genetic determinants of drug response at the single gene leveland its impact on pharmaceuticals, therapeutics, and clinical practice. Providing an overview of the molecular basis of pharmacogenetics, the book helps readers understand the implications of genetic variability on pharmacokinetics and pharmacodynamics, as well as other aspects such as adverse drug reactions. Providing coverage of specific disease areas, including cardiovascular concerns, cancer and asthma/COPD, transplantation, and pain medication, the book also looks at the clinical practices, along with the psychiatric and ethical issues that have come to dominate conversation about pharmacogenetics.

The technological applications of pharmacogenetics, including genotyping, drug disposition (metabolism and enzymes), and the impact of this research on the pharmaceutical industry and regulatory matters are all addressed in chapters by internationally recognized leaders from both academia and industry.

Including chapters on specific therapeutic areas and clinical aspects, Pharmacogenetics and Individualized Therapy helps readers, whether they're students or researchers, to understand the implications of genetic variability on pharmacokinetics and pharmacodynamics.

Authors

ANKE-HILSE MAITLAND-van der ZEE, PhD, is Associate Professor of Pharmacogenetics

Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PhD, is Professor of Pharmacogenetics at Newcastle University, UK.

See more here:
Research and Markets: Pharmacogenetics and Individualized Therapy

Comments are closed.